Lecture Series: "Systems Biologics: Large-Scale Engineering of Modulators of Protein Networks"

Over the past two decades, genomics technologies have revolutionized basic research and are also having a significant impact on understanding, predicting and diagnosing disease. Over the same period, the biologics revolution, lead by therapeutic antibodies, has greatly expanded our ability to target proteins that drive cancer and other diseases. To date, however, the academic genomics revolution and the industrial biologics revolutions have not been combined, so that the vast amounts of data generated by genomics technology have not been effectively translated to drug development, which remains a slow, case-by-case process. We established the Toronto Recombinant Antibody Centre (TRAC) to combine large-scale systems biology approaches with the discovery and development of new antibody drugs. The efficient pipeline of (1) basic research, connected to (2) translational science, and (3) commercialization, constitutes a new model for research and drug development, which we have termed “Systems Biologics”. Through this model, cutting-edge systems biology basic research can be seamlessly translated into systems biologics: novel, multi-functional drugs and diagnostics that take advantage of the complexities of human biology revealed by genomics data.

Join Zoom Meeting
https://umd.zoom.us/j/98986478678?pwd=RlJmRnQxSFlxRUkrNU8zd0doczArZz09

Meeting ID: 989 8647 8678
Passcode: 436361

One tap mobile
+13017158592,,98986478678# US (Washington DC)
+13126266799,,98986478678# US (Chicago)

Dial by your location
        +1 301 715 8592 US (Washington DC)
        +1 312 626 6799 US (Chicago)
        +1 929 436 2866 US (New York)
        +1 346 248 7799 US (Houston)
        +1 669 900 6833 US (San Jose)
        +1 253 215 8782 US (Tacoma)